An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry
Reference43 articles.
1. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer;Shu;Nature,2016
2. BET family protein BRD4: An emerging actor in NFκB signaling in inflammation and cancer;Hajmirza;Biomedicines,2018
3. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA;Zou;Oncogene,2014
4. Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation;Tian;Cell Rep.,2018
5. Brd4 is on the move during inflammation;Xu;Trends Cell Biol.,2014
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Probing the AFF4–CCNT1 protein–protein interaction using a metal–organic conjugate for treating triple-negative breast cancer;Chemical Engineering Journal;2024-09
2. Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications;Frontiers in Bioscience-Landmark;2024-08-19
3. Optical controlled and nuclear targeted CECR2 competitor to downregulate CSF-1 for metastatic breast cancer immunotherapy;Biomaterials;2024-07
4. The emerging role of deubiquitylating enzyme USP21 as a potential therapeutic target in cancer;Bioorganic Chemistry;2024-06
5. The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities;Genes & Diseases;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3